P276-00是一种新型的CDK1,CDK4和CDK9抑制剂,IC50分别为79 nM, 63 nM和20 nM。
P276-00 is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. Phase 2/3.
~5.0 μM
50 mg/kg 每天一次,或30 mg/kg 每天两次腹腔注射
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Joshi KS, et al. Mol Cancer Ther, 2007, 6(3), 918-925.
分子式 C21H20ClNO5.HCl |
分子量 438.3 |
CAS号 920113-03-7 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 80 mg/mL |
Water 80 mg/mL |
Ethanol 5 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT00898287 | Pancreatic Cancer | Drug: P276-00|Drug: Gemcitabine | Piramal Enterprises Limited | Phase 1|Phase 2 | 2009-05-01 | 2012-01-19 |
NCT00899054 | Squamous Cell Carcinoma of Head and Neck | Drug: P276-00|Radiation: External beam radiotherapy (EBRT) | Piramal Enterprises Limited | Phase 1|Phase 2 | 2009-08-01 | 2012-11-21 |
NCT00882063 | Relapsed and/or Refractory Multiple Myeloma | Drug: P276-00 | Piramal Enterprises Limited | Phase 1|Phase 2 | 2008-01-01 | 2012-11-20 |
NCT00843050 | Mantle Cell Lymphoma | Drug: P276-00 | Piramal Enterprises Limited | Phase 2 | 2009-11-01 | 2012-06-20 |
NCT00835419 | Melanoma | Drug: P276-00 | Piramal Enterprises Limited | Phase 2 | 2009-05-01 | 2012-12-03 |
NCT00824343 | Squamous Cell Carcinoma of Head and Neck | Drug: P276-00 | Piramal Enterprises Limited | Phase 2 | 2008-09-01 | 2013-07-08 |
NCT00407498 | Neoplasm | Drug: P276-00 | Piramal Enterprises Limited | Phase 1 | 2005-05-01 | 2008-12-31 |
NCT00547404 | Multiple Myeloma | Drug: P276-00 | Piramal Enterprises Limited | Phase 1 | 2008-12-01 | 2009-04-21 |
NCT01333137 | Breast Cancer | Drug: Gemcitabine and Carboplatin|Drug: P276-00 along with Gemcitabine and carboplatin | Piramal Enterprises Limited | Phase 1 | 2011-08-01 | 2014-09-03 |
NCT00408018 | Neoplasm | Drug: P276-00 | Piramal Enterprises Limited | Phase 1 | 2006-03-01 | 2008-12-31 |
NCT01903018 | Radiation Induced Mucositis in Head and Neck Cancer | Drug: P276-00|Radiation: Radiation Therapy|Drug: Cisplatin | Piramal Enterprises Limited | Phase 2 | 2012-07-01 | 2014-09-03 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们